Considerations in Sequencing BCMA-Targeting Bispecifics and CAR-T Therapies in R/R MM
Myeloma specialists discuss considerations they consider when determining how they sequence CAR T-cell therapies and bispecific antibodies.
EP: 1.Advancements in the Treatment of Newly Diagnosed MM: Updates from the Phase 3 IMROZ Study
EP: 2.Navigating Treatment Advancements and Recent Approvals in R/R Multiple Myeloma: Expert Insights
EP: 3.Updates From the Phase 2 MonumenTAL-2 Study Investigating Talquetamab in R/R MM
EP: 4.Long-Term Follow-up with Teclistamab in R/R MM: Updates from MajesTEC-1
EP: 5.Treatment Strategies with Elranatamab in R/R MM: Updates from the MagnetisMM Trials
EP: 6.Expert Perspectives: Sequencing Approaches with CAR-T and Bispecifics in R/R MM
EP: 7.Expert Insights: Strategies for Step-Up Dosing and Long-Term Treatment Management with Bispecifics in R/R MM
EP: 8.The Role of MRD Testing in Guiding Treatment in R/R MM: ASCO 2024 Updates from PERSEUS
Now Viewing
EP: 9.Considerations in Sequencing BCMA-Targeting Bispecifics and CAR-T Therapies in R/R MM
EP: 10.Cilta-cel in R/R MM: ASCO 2024 Updates from CARTITUDE Trials
EP: 11.AE Management for CAR-T Therapy: Expert Insights and Perspectives
EP: 12.Looking Ahead: ASCO 2024 Updates and Future Perspectives
EP: 13.Key Takeaways and Clinical Pearls on the Treatment of R/R MM in the Era of Bispecifics
EP: 14.Bispecific Antibodies Are Taking the Multiple Myeloma World by Storm
Video content above is prompted by the following questions:
- Can BCMA-targeting bispecifics be used in patients who have received prior BCMA-targeting CAR-T therapies?
- Might you consider a different target?
- Might you consider a different target?
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
